TBF1 Stock Overview
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Canntab Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.024 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.17 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.92% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| TBF1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.8% |
| 1Y | 0% | -27.7% | 2.2% |
Return vs Industry: TBF1 exceeded the German Pharmaceuticals industry which returned -24.8% over the past year.
Return vs Market: TBF1 underperformed the German Market which returned 7% over the past year.
Price Volatility
| TBF1 volatility | |
|---|---|
| TBF1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TBF1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TBF1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Goldstein | canntab.ca |
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Canntab Therapeutics Limited Fundamentals Summary
| TBF1 fundamental statistics | |
|---|---|
| Market cap | €132.99k |
| Earnings (TTM) | -€2.29m |
| Revenue (TTM) | €50.23k |
2.6x
P/S Ratio-0.1x
P/E RatioIs TBF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBF1 income statement (TTM) | |
|---|---|
| Revenue | CA$73.48k |
| Cost of Revenue | CA$1.40m |
| Gross Profit | -CA$1.33m |
| Other Expenses | CA$2.03m |
| Earnings | -CA$3.36m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | -1,806.30% |
| Net Profit Margin | -4,566.80% |
| Debt/Equity Ratio | -87.8% |
How did TBF1 perform over the long term?
See historical performance and comparison